Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:OPHT

IVERIC bio (OPHT) Stock Price, News & Analysis

IVERIC bio logo

About IVERIC bio Stock (NASDAQ:OPHT)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$1.13
$1.39
52-Week Range
N/A
Volume
N/A
Average Volume
159,109 shs
Market Capitalization
$1.65 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

IVERIC bio, Inc. is a biopharmaceutical company which engages in discovering, developing, and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in New York, NY.

Receive OPHT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IVERIC bio and its competitors with MarketBeat's FREE daily newsletter.

OPHT Stock News Headlines

Gossamer Bio Inc GOSS
Warning: Elon’s $20k Robot Might Replace Your Nanny
Tesla’s Robot Revolution Has Begun It’s official… Tesla’s robot revolution is underway… By the end of this year, Tesla plans to produce 600 new “Tesla Bots” per week… Tech insiders believe this could be the company’s next core driver of explosive growth. Some even believe it could be the catalyst that would push shares above the $1,000 mark. That’s essentially a 100% increase from today’s price…
Baird Downgrades IVERIC bio (ISEE)
See More Headlines

OPHT Stock Analysis - Frequently Asked Questions

IVERIC bio, Inc. (NASDAQ:OPHT) posted its quarterly earnings data on Wednesday, October, 31st. The biopharmaceutical company reported ($0.41) EPS for the quarter, beating analysts' consensus estimates of ($0.43) by $0.02.

Based on aggregate information from My MarketBeat watchlists, some other companies that IVERIC bio investors own include iShares Preferred and Income Securities ETF (PFF), Puma Biotechnology (PBYI), Incyte (INCY), Apollo Investment (AINV), BioMarin Pharmaceutical (BMRN), Meta Platforms (META) and Bristol-Myers Squibb (BMY).

Company Calendar

Last Earnings
10/31/2018
Today
2/22/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:OPHT
Fax
N/A
Employees
35
Year Founded
N/A

Profitability

Net Income
$63.09 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$209.98 million
Book Value
$3.00 per share

Miscellaneous

Free Float
N/A
Market Cap
$1.65 billion
Optionable
Optionable
Beta
1.49
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:OPHT) was last updated on 2/22/2025 by MarketBeat.com Staff
From Our Partners